Formulation design of an HPMC-based sustained release tablet for pyridostigmine bromide as a highly hygroscopic model drug and its in vivo/in vitro dissolution properties

Drug Development and Industrial Pharmacy

Volumn 33, Issue 11, 2007, Pages 1183-1191

  Huang, Yuh Tyng ^a   Tsai, Tong Rong ^a   Cheng, Chun Jen ^a   Cham, Thau Ming ^a,d   Lai, Tsun Fwu ^b   Chuo, Wen Ho ^c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN INSTITUTE OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c TAJEN UNIVERSITY   (Taiwan)

^d NONE   (Taiwan)

Author keywords

23 full factorial design; Direct compression method; Highly hygroscopic drug; In vitro in vivo relationship; Sustained release tablet; Zero order mechanism

Indexed keywords

EXCIPIENT; PYRIDOSTIGMINE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; NONHUMAN; RABBIT; SUSTAINED DRUG RELEASE; TABLET FORMULATION;

ANIMALS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; EXCIPIENTS; METHYLCELLULOSE; PYRIDOSTIGMINE BROMIDE; RABBITS; SOLUBILITY; TABLETS;

EID: 36749051224     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701377334     Document Type: Article

References (35)

1. Alderman, D. A. (1984). A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int. J. Pharm. Tech. Prod. Mfr., 5, 1-9.
2. Bodmeier, R. (1997). Tableting of coated pellets. Eur. J. Pharm. Biopharm., 43(1), 1-8.
3. Chopra, R., Alderborn, G., Podczeck, F., & Newton, J. M. (2002). The influence of pellet shape and surface properties on the drug release from uncoated and coated pellets. Int. J. Pharm., 239(1-2), 171-178.
4. Chuo, W. H., Tsai, T. R., & Cham, T. M. (1998). The investigation of the internal structure and release behavior of tablets compressed by nifedipine-loaded albumin microspheres. Pharmazie., 53(2), 104-110.
5. Engineer, S., Shao, Z. J., & Khagani, N. A. (2004). Temperature/humidity sensitivity of sustained-release formulations containing Kollidon® SR. Drug Dev. Ind. Pharm., 30(10), 1089-1094.
6. Ford, J. L., Rubinstein, M. H., & Hogan, J. E. (1985). Formulation of sustained-release promethazine hydrochloride tablets using hydroxypropylmethylcellulose matrices. Int. J. Pharm., 24(2-3), 327-338.
7. Gandhi, R., Kaul, C. L., & Panchagnula, R. (1999). Extrusion and spheronization in the development of oral controlled-release dosage forms. Pharm. Sci. Technol. Today, 2(1), 160-170.
8. Hegazy, N., Demirel, M., & Yazan, Y. (2002). Preparation and in vitro evaluation of pyridostigmine bromide microparticles. Int. J. Pharm., 242(1-2), 171-174.
9. Hogan, J. E. (1989). Hydroxypropyl-methylcellulose sustained-release technology. Drug Dev. Ind. Pharm., 15(6), 975-999.
10. Huang, Y. B., Tsai, Y. H., Yang, W. C., Chang, J. S., Wu, P. C., & Takayama, K. (2004). Once-daily propranolol extended-release tablet dosage form: Formulation design and in vitro/in vivo investigation. Eur. J. Pharm. Biopharm., 58(3), 607-614.
11. Huang, Y. T., Lai, T. F., Tsai, T. R., Cheng, C. J., Chuo, W. H., & Cham, T. M. (2007). Formulation design of a highly hygroscopic drug (pyridostigmine bromide) for its hygroscopic character improvement and investigate of in vitro/in vivo dissolution properties. Drug Dev. Ind. Pharm., 33(4), 1-14.
12. Kim, H., & Fassihi, R. (1997). A new ternary polymeric matrix system for controlled drug delivery of highly soluble drugs: I. Diltiazem hydrochloride. Pharm. Res., 14(10), 1415-1421.
13. Lee, P. I. (1985). Kinetics of drug release from hydrogel matrices. J. Control. Release., 2(2), 277-288.
14. Lee, B. J., Ryu, S. G., & Cui, J. H. (1999). Formulation and release characteristics of hydroxypropyl-methylcellulose matrix tablet containing melatonin. Drug Dev. Ind. Pharm., 25(4), 493-501.
15. Li, S., Lin, S., Daggy, B. P., Mirchandani, H. L., & Chien, Y. W. (2003). Effect of HPMC and Carbopol on the release and floating properties of gastric floating drug delivery systems using factorial design. Int. J. Pharm., 253(1-2), 13-22.
16. Lin, A. Y., Muhammad, N. A., Pope, D., & Augsburger, L. L. (2003). A study of the effects of curing and storage conditions on controlled release diphenhydramine HCl pellets coated with Eudragit® NE30D. Pharm. Dev. Tech., 8(3), 277-287.
17. Lundqvist, Å. E. K., Podczeck, F., & Newton, J. M. (1997). Influence of disintegrant type and proportion on the properties of tablets produced from mixtures of pellets. Int. J. Pharm., 147(1), 95-107.
18. Maejima, T., & McGinity, J. W. (2001). Influences of film additives on stabilizing drug release rates from pellets coated with acrylic polymers. Pharm. Dev. Technol., 6(2), 211-221.
19. McEvoy, G. (1992). Pyridostigmine Bromide. In G. K. McEvoy (Ed.), AHFS Drug Information (pp. 630-632). Bethesda, MD: American Society of Hospital Pharmacists, Inc.
20. Michaelis, H. C. (1990). Determination of pyridostigmine plasma concentrations by high-performance liquid chromatography. J. Chromatogr., 534(1), 291-294.
21. k factorial design: Design and analysis of experiments (pp. 290-294). New York: John Wiley & Sons.
22. Peppas, N. A., & Sahlin, J. J. (1989). A simple equation for the description of solute release, III. Coupling of diffusion and relaxation. Int. J. Pharm., 57(2), 169-172.
23. Qiu, Y., Cheskin, H. S., Engh, K. R., & Poska, R. P. (2003). Once-a-day controlled release dosage form of divalproex sodium I: Formulation design and in vitro/in vivo investigations. J. Pharm. Sci., 92(6), 1166-1173.
24. Rao, Y. M., Veni, J. K., & Jayasagar, G. (2001). Formulation and Evaluation of Diclofenac Sodium Using Hydrophilic Matrices. Drug Dev. Ind. Pharm., 27(8), 759-766.
25. Ritger, P. L., & Peppas, N. A. (1987a). A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinder or discs. J. Control. Release., 5(1), 23-36.
26. Ritger, P. L., & Peppas, N. A. (1987b). A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Release., 5(1), 37-42.
27. Sánchez-Lafuente, C., Furlanetto, S., Fernández- Arévalo, M., Alvarez-Fuentes, J., Rabasco, A. M., Faucci, M. T., Pinzauti, S., & Mura, P. (2002). Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design. Int. J. Pharm., 237(1-2), 107-118.
28. Sung, K. C., Nixon, P. R., Skoug, J. W., Ju, T. R., Gao, P. E., Topp, M., & Patel, M. V. (1996). Effect of formulation variables on drug and polymer release from HPMC-based matrix tablets. Int. J. Pharm., 142(1), 53-60.
29. Takka, S., Sakr, A., & Goldberg, A. (2003). Development and validation of an in vitro-in vivo correlation for buspirone hydrochloride extended release tablets. J. Control. Release, 88(1), 147-157.
30. United States Food and Drug Administration (FDA). Guidance for industry, dissolution testing of IR solid oral dosage forms, 1997.
31. United States Food and Drug Administration (FDA). Pyridostigmine Bromide Package Insert, 2002.
32. United States Food and Drug Administration (FDA). FDA approves PB as pretreatment against nerve gas, 2003.
33. Vazquez, M. J., Perez-Marcos, B., Gomez-Amoza, J. L., Martinez-Pacheco, R., Souto, C., & Concheiro, A. (1992). Influence of technological variables on release drugs from hydrophilic matrices. Drug Dev. Ind. Pharm., 18(11-12), 1355-1375.
34. Vervaet, C., Baert, L., & Remon, J. P. (1995). Extrusion- spheronisation a literature review. Int. J. Pharm., 116(2), 131-146.
35. Wanger, J., & Nelson, E. (1964). Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J. Pharm. Sci., 53(11), 1392-1404.